News Releases

News Releases

Date Title
May 21, 2019 Sesen Bio Announces Acceptance of Analytical Comparability Plan by the U.S. Food and Drug Administration to Support the BLA and Commercialization of Its Lead Asset, Vicinium® for Non-Muscle Invasive Bladder Cancer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 21, 2019-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company has completed its Type C CMC meeting and has reached agreement with
May 13, 2019 Sesen Bio Reports First Quarter 2019 Financial Results and Updated, Preliminary Primary and Additional Secondary Endpoint Data from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer
Company Announces Confirmed Meetings with the U.S. Food and Drug Administration in May and June 2019 to Review Registration Strategy for Vicinium ® Management to Host a Business Update Call Today at 8:00 a.m. EDT CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 13, 2019-- Sesen Bio (Nasdaq:SESN), a
Apr 29, 2019 Sesen Bio to Host Conference Call to Review First Quarter 2019 Financial Results and Updated Preliminary Data from Phase 3 VISTA Trial
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 29, 2019-- Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Monday, May 13,
Mar 4, 2019 Sesen Bio Reports Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial
Company Announces Additional Key Primary and Secondary Endpoints Further Supporting Vicinium ® Treatment Potential in High-Risk Non-Muscle Invasive Bladder Cancer Company on Track to Report Updated 12-Month Data from Phase 3 VISTA Trial of Vicinium in Mid-2019 Management to Host a Business Update
Feb 25, 2019 Sesen Bio to Host Conference Call to Review Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2019-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of people with cancer, today announced that Company management will host a conference call and webcast on Monday, March 4,
Jan 3, 2019 Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer
Complete Response Rates from All Four Time Points in Carcinoma in Situ Patients In-line with Phase 2 Data Company to Host Conference Call Today, January 3 , at 8:30 a.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2019-- Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company advancing
Displaying 11 - 16 of 16
Top